In a study published in Nature Immunology on January 6, a research team led by Prof. Qian Youcun from the Shanghai Institute ...
Researchers reveal a novel natural “decoy receptor” that protects against inflammatory bowel disease
A research team led by Prof. QIAN Youcun from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences identified a new member of the human IL -17 receptor ...
The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...
Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz ...
GlobalData on MSN
Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study
These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.
The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
NEMLUVIO is the first authorized monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling ...
The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...
MedPage Today on MSN
CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma
Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...
12d
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback